THOR Study: A Study of Continued Herceptin (Trastuzumab) in Combination With Second Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.

NCT00448279 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

58

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: trastuzumab
DRUG: Chemotherapy

Sponsor

Hoffmann-La Roche